-
1.发明公开
公开(公告)号：EP3374518A1
公开(公告)日：2018-09-19
申请号：EP16793890.1
申请日：2016-11-09
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paris Descartes , Assistance Publique-Hôpitaux de Paris (APHP) , Université Paris Diderot - Paris 7
IPC分类号： C12Q1/68
摘要： The present invention relates to methods for predicting the survival time of patients with decompensated alcoholic cirrhosis. In particular, the present invention relates to a method for predicting the survival time of a patient with decompensated alcoholic cirrhosis comprising i) determining the expression level of OAS2 or MX2 in a sample of peripheral blood mononuclear cells obtained from the patient, ii) comparing the level determined at step i) with a predetermined reference value and iii) and concluding that the patient will have a short survival time when the level determined at step i) is higher than its predetermined reference value or concluding that the patient will have a long survival time when the level determined at step i) is lower than the predetermined reference value.
-
2.发明公开
公开(公告)号：EP3602066A1
公开(公告)日：2020-02-05
申请号：EP18710905.3
申请日：2018-03-20
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paris Descartes , Assistance Publique-Hôpitaux de Paris (APHP) , Université Paris Diderot - Paris 7
IPC分类号： G01N33/68
-
3.发明授权
公开(公告)号：EP3374518B1
公开(公告)日：2019-11-06
申请号：EP16793890.1
申请日：2016-11-09
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paris Descartes , Assistance Publique-Hôpitaux de Paris (APHP) , Université Paris Diderot - Paris 7
IPC分类号： C12Q1/6883
-
4.发明公开METHODS AND KITS FOR DETERMINING WHETHER A PATIENT WITH CIRRHOSIS IS AT RISK OF HAVING CLINICALLY SIGNIFICANT PORTAL HYPERTENSION 有权VERFAHREN ZUR BESTIMMUNG DES RISIKOS EINES KLINISCH BEDEUTSAMEN PFORTADERHOCHDRUCKS EINES ZIRRHOSEPATITENTEN
公开(公告)号：EP2807488A2
公开(公告)日：2014-12-03
申请号：EP13701283.7
申请日：2013-01-28
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , Université Paris Diderot (Paris 7) , Université de Versailles Saint-Quentin-en-Yvelines , Université Paris Descartes , Assistance Publique - Hôpitaux de Paris
IPC分类号： G01N33/68 , G01N33/50 , G01N33/569
CPC分类号： G01N33/6893 , G01N33/56966 , G01N2333/4742 , G01N2333/70503 , G01N2333/70514 , G01N2333/70553 , G01N2333/70596 , G01N2800/085
摘要： The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41−), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.
摘要翻译： 本发明涉及一种用于确定肝硬化患者是否处于具有临床意义上的门静脉高压的风险的方法，其包括以下步骤：i）量化白细胞内皮（CD31 + / 41-），泛白细胞（CD11a +）， ，从患者获得的血液样品中的淋巴细胞（CD4 +），红细胞（CD235a +）和肝细胞衍生的（细胞角蛋白-18 +）微粒，以及ii）将所述水平与预定参考值进行比较，其中步骤i） 并且预定的参考值指示患者是否具有临床上显着的门静脉高压的风险。
-
公开(公告)号：EP3602059A1
公开(公告)日：2020-02-05
申请号：EP18711351.9
申请日：2018-03-20
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paris Descartes , Assistance Publique-Hôpitaux de Paris (AP-HP) , Université Paris Diderot Paris 7
IPC分类号： G01N33/574
-
6.发明授权
公开(公告)号：EP2807488B1
公开(公告)日：2018-01-10
申请号：EP13701283.7
申请日：2013-01-28
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , Université Paris Diderot (Paris 7) , Université de Versailles Saint-Quentin-en-Yvelines , Université Paris Descartes , Assistance Publique - Hôpitaux de Paris
IPC分类号： G01N33/68 , G01N33/50 , G01N33/569
CPC分类号： G01N33/6893 , G01N33/56966 , G01N2333/4742 , G01N2333/70503 , G01N2333/70514 , G01N2333/70553 , G01N2333/70596 , G01N2800/085
摘要： The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41−), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.
-
公开(公告)号：EP2836219A1
公开(公告)日：2015-02-18
申请号：EP13715217.9
申请日：2013-04-10
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , Université Paris Descartes
IPC分类号： A61K31/7088 , A61K31/7105 , C12N15/113
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/7125 , A61K31/713 , A61K48/00 , C12N7/00 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12N2710/10042 , C12N2710/16142 , C12N2710/16442 , C12N2740/15042
摘要： The present invention relates to the treatment of nonalcoholic steatohepatitis (NASH), in particular to a compound that inhibits mi R-21expressionfor use in the treatment of nonalcoholic steatohepatitis.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.024 秒)
